Sarepta Therapeutics Inc. (NASDAQ:SRPT) CEO Edward M. Md Kaye sold 40,179 shares of Sarepta Therapeutics stock in a transaction dated Thursday, September 22nd. The shares were sold at an average price of $60.00, for a total value of $2,410,740.00. Following the completion of the transaction, the chief executive officer now owns 117,162 shares in the company, valued at approximately $7,029,720. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Sarepta Therapeutics Inc. (NASDAQ:SRPT) opened at 60.98 on Friday. Sarepta Therapeutics Inc. has a one year low of $8.00 and a one year high of $63.73. The firm’s market capitalization is $2.92 billion. The firm has a 50-day moving average price of $34.86 and a 200-day moving average price of $23.51.
Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings results on Tuesday, July 19th. The company reported ($1.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.19) by $0.16. During the same quarter in the prior year, the business earned ($0.87) earnings per share. Equities analysts anticipate that Sarepta Therapeutics Inc. will post ($4.13) earnings per share for the current year.
SRPT has been the topic of several analyst reports. JMP Securities upgraded Sarepta Therapeutics to an “outperform” rating and lifted their target price for the company from $10.00 to $60.00 in a research note on Monday, September 19th. Royal Bank Of Canada upgraded Sarepta Therapeutics from a “sector perform” rating to an “outperform” rating and set a $83.00 price target on the stock in a research note on Monday, September 19th. Leerink Swann restated an “underperform” rating and set a $5.00 price target on shares of Sarepta Therapeutics in a research note on Thursday, August 4th. Robert W. Baird restated an “outperform” rating and set a $23.00 price target on shares of Sarepta Therapeutics in a research note on Monday, July 18th. Finally, Oppenheimer Holdings Inc. restated an “outperform” rating and set a $60.00 price target on shares of Sarepta Therapeutics in a research note on Tuesday, July 26th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $50.28.
A number of large investors have recently bought and sold shares of SRPT. First Midwest Bank Trust Division raised its stake in Sarepta Therapeutics by 36.2% in the second quarter. First Midwest Bank Trust Division now owns 32,954 shares of the company’s stock worth $628,000 after buying an additional 8,754 shares in the last quarter. American Century Companies Inc. bought a new stake in Sarepta Therapeutics during the second quarter worth about $651,000. Eagle Asset Management Inc. bought a new stake in Sarepta Therapeutics during the second quarter worth about $6,756,000. Amici Capital LLC bought a new stake in Sarepta Therapeutics during the first quarter worth about $488,000. Finally, LGL Partners LLC raised its stake in Sarepta Therapeutics by 4.2% in the first quarter. LGL Partners LLC now owns 24,862 shares of the company’s stock worth $485,000 after buying an additional 1,000 shares in the last quarter. 72.09% of the stock is currently owned by institutional investors.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.
Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.